Mirataz™(mirtazapine transdermal ointment)

Mirataz is transdermal mirtazapine, formulated with KindredBio’s proprietary Accusorb™ technology, being developed for the management of weight loss in cats.

Unexpected weight loss and anorexia occur commonly in cats due to various causes and are estimate occur in millions of cats per year, 1,2 and, can result in serious outcomes including hepatic lipidosis/liver failure and death.3 Managing weight loss in cats may help to avoid clinically significant metabolic changes and may improve the cat’s longevity and quality of life.  There is currently no approved veterinary drug for these conditions. KindredBio’s application for Mirataz is currently under review at the FDA Center for Veterinary Medicine (CVM). Approval and launch of the drug is expected in 2018.

1 U.S. Veterinarian Mirtazapine Phase 2 Research, Wise Insights, May 2016 (n=89 U.S. small animal veterinarians).  U.S. Veterinarian Mirtazapine Phase Research, Ipsos, September 2016 (n=201 U.S. small animal veterinarians). Data on file at KindredBio.

2 Freeman LM et al.  Evaluation of weight loss over time in cats with chronic kidney disease.  J Vet Int Med. 2016; 30:1661-1666.

3 Agnew W and Kirman R.  Pharmacological appetite stimulation: rationale choices in the inappetent cat.  J Feline Med Surg. 2014;16(9):749-56.

4 Quimby JM and Lunn KE.  Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013;197(3):651-5.

5 Benson KK et al. Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. J Fel Med Surg. 2017;19(10):998-1006.